Plasma Thymidine Kinase Activity in Dogs with Lymphoma and Leukemia.

Nakamura, Noriko; Momoi, Yasuyuki; Watari, Toshihiro; Yoshino, Toshio; Tsujimoto, Hajime; Hasegawa, Atsuhiko

doi:10.1292/jvms.59.957

Cited by 32 publications

(55 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These authors used 6.0 U/L as the upper limit of the reference range for clinically healthy dogs, which is close to the 7.0 U/L reported here. Nakamura et al 10 found that plasma TK was increased in all dogs with ML and leukemia, and thus might be a marker for prediction of tumor proliferation. Furthermore, TK was demonstrated to be a much better tumor marker than serum lactate dehydrogenase (LDH) for evaluation of disease progression.…”

Section: Discussionmentioning

confidence: 99%

“…8,9,27 Thus, NHL is similar in dogs and humans. In dogs 10 and humans, 28 patients with inflammatory changes and nonneoplastic leukocytosis can have short, transient increases in sTK activity, which returns to normal when the leukocytosis resolves. Hence, a group of 7 dogs with nonneoplastic leukocytosis was included.…”

Section: Discussionmentioning

confidence: 99%

“…9 On the other hand, only 1 report with a limited number of cases has so far described thymidine kinase activity in dogs with ML. 10 In humans, the use of tumor markers is widely applied and considered as a clinical standard for many neoplasms. Many hematopoietic malignancies are characterized by a very high rate of cell proliferation.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Serum Thymidine Kinase Activity in Dogs with Malignant Lymphoma: A Potent Marker for Prognosis and Monitoring the Disease

Euler

Einarsson²,

Olsson

et al. 2004

Veterinary Internal Medicne

View full text Add to dashboard Cite

Serum thymidine kinase (sTK) activity was evaluated as a tumor marker for canine malignant lymphoma (ML). The objective was to investigate if sTK, as in humans, could be used as a prognostic marker for survival time in dogs with ML and if sTK could identify early signs of progression of disease in treated dogs. Serum samples from 52 dogs with ML were tested for initial TK activity. Samples from 21 normal dogs and 25 dogs with nonhematologic neoplasms were used for comparison. Forty-four dogs with ML were treated. Serum TK activity was measured in treated dogs before each treatment and every 4 weeks thereafter until relapse. Dogs with ML had 2-180 times higher TK activity (TK 5-900 U/L) than normal dogs (TK Ͻ7 U/L) based on the mean ϩ 2 standard deviations. In the group of other neoplasms, only 2 dogs had a moderate increase (6.4 and 7.5 U/L) compared with the controls. Mean sTK activities in the dogs with ML that had gone into complete remission (CR) were not significantly different from activities in healthy controls (P ϭ .68). Mean sTK at least 3 weeks before and at the time of relapse was significantly higher than activity measured at CR (P Ͻ .0001). Dogs with ML that initially had sTK Ͼ30 U/L had significantly shorter survival times (P Ͻ .0001). Furthermore, sTK activity reflected the clinical staging of ML. Measuring sTK can be used as a powerful objective tumor marker for prognosis and for predicting relapse before recurrence of clinically detectable disease in dogs with ML undergoing chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Thymidine Kinase Activity in Dogs with Malignant Lymphoma: A Potent Marker for Prognosis and Monitoring the Disease

Euler

Einarsson²,

Olsson

et al. 2004

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…The results published in this issue of the journal offer cautious optimism for sTK as a useful marker of disease activity in dogs with lymphoma, and build on a previous publication on a similar theme. 5 In the data presented in this study, sTK activity correlated with clinical stage of disease at the time of diagnosis, decreased to physiological activity after clinical remission was achieved, and served to portend clinical relapse. Therefore, measurements of sTK might allow recognition of which patients might benefit from early or intensified treatment.…”

mentioning

confidence: 60%

Serum Thymidine Kinase Activity: An Alternative to Histologic Markers of Cellular Proliferation in Canine Lymphoma

Madewell

2004

Veterinary Internal Medicne

View full text Add to dashboard Cite

Thymidine kinase (TK) is a cellular enzyme which is involved in a salvage pathway of DNA synthesis. It is activated in the G1/S phase of the cell cycle, and its activity has been shown to correlate with the proliferative activity of tumor cells⃜Clin‐ical studies have reported high serum TK concentrations in a variety of neoplasias. The majority of these studies concerned hematological malignancies. TK seems to be a useful marker in non‐Hodgkins lymphoma, where it correlates with clinical stag‐ing and provides marked prognostic information on (progres‐sion‐free) survival.

show abstract

“…The numbers of erythroid progenitors with large, irregular nuclei were increased in peripheral blood. Plasma thymidine kinase activity was high (636 IU/l) compared with clinically healthy control cats (<5 IU/l: n=22) 46 days after the 1st examination, indicating a myeloproliferative condition, as shown in other species [4,5,8]. The cat was regarded as having an MDS-like condition and was treated with low-dose cytarabine (20 mg/m 2 q24h subcutaneously) with reference to treatment for human MDS patients [7,13].…”

mentioning

confidence: 99%

Abnormal Erythroid Cell Proliferation and Myelofibrosis in a Cat

Iwanaga

Miura

Miyoshi

et al. 2012

The Journal of Veterinary Medical Science

Self Cite

View full text Add to dashboard Cite

ABSTRACT. A cat was presented with severe progressive anemia despite marked erythroblastosis. The cat was negative for feline leukemia virus antigen and feline immunodeficiency virus antibody. Bone marrow cytology revealed an excess of erythroid cells with a predominance of prorubricytes and basophilic rubricytes. No response to immunosuppressive therapy was obtained, and a tentative diagnosis of myelodysplastic syndrome was made. The cat showed a partial response to low-dose cytarabine (20 mg/m 2 subcutaneously q24) but died 51 days after the 1st admission. Histopathological examination revealed fibrosis in the bone marrow and marked infiltration of erythroid cells into other organs.

show abstract

Plasma Thymidine Kinase Activity in Dogs with Lymphoma and Leukemia.

Cited by 32 publications

References 13 publications

Serum Thymidine Kinase Activity in Dogs with Malignant Lymphoma: A Potent Marker for Prognosis and Monitoring the Disease

Serum Thymidine Kinase Activity in Dogs with Malignant Lymphoma: A Potent Marker for Prognosis and Monitoring the Disease

Serum Thymidine Kinase Activity: An Alternative to Histologic Markers of Cellular Proliferation in Canine Lymphoma

Abnormal Erythroid Cell Proliferation and Myelofibrosis in a Cat

Contact Info

Product

Resources

About